British Biotech Pharmaceuticals Limited

British Bio-technology Limited

Isis Innovation Limited

British Biotech

Michael George Hunter

Mark Whittaker

John Martin Clements

Raymond Paul Beckett

Zoe Marie Spavold

Richard Mark Edwards

Lisa Marie Pratt

Steven Launchbury

Stephen John Davies

Keith Martyn Dawson

Richard James Gilbert

Lloyd George Czaplewski

Paul Raymond Beckett

Stewart Craig

Lars Michael Wood

Michael Berisford Comer

Martin John Clements

Matthew John McCourt

Lloyd G Czaplewski

Compounds of formula (I) or a pharmaceutically or veterinarily acceptable salts thereof wherein Rrepresents hydrogen, C-Calkyl or C-Calkyl substituted by one or more halogen atoms; Rrepresents a group R-(ALK)-, and A represents (i) a group of formula (IA): wherein the compounds inhibit the activity of bacterial PDF enzyme.

Antibacterial agents

A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof: 

Hydroxamic acid derivatives as antibacterials

A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof for the inhibition of activity of bacterial PDF enzyme: wherein A represents a group of formula (IA) or (IB) and wherein Ris hydrogen, Ris n-butyl, benzyl or cyclopentylmethyl, Ris hydrogen, Ris tert-butyl, iso-butyl, benzyl or methyl, Ris hydrogen or methyl and Ris methyl.

A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:

Selected compounds of formula (I) are antibacterial agents: formula (I) wherein Rrepresents a substituted or unsubstituted C-Calkyl, cycloalkyl (C-Calkyl)- or aryl (C-Calkyl)-group, and A represents a group of formula (IA), or (IB) wherein Rrepresents the side chain of a natural or non-natural alpha amino acid, and Rand Rare each independently hydrogen or C-Calkyl, heterocyclic or aryl (C-Calkyl)-, Rand Rwhen taken together with the nitrogen atom to which they are attached from an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring

A hybrid fusion protein comprising a first antigenic amino acid sequence fused to a second amino acid sequence substantially homologous to B2M or a fragment thereof.

Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin

Antibacterial hydroxamic acid derivatives

Compounds of formula (I) are in the preparation of antibacterial agents, wherein: R represents hydrogen, C -C alkyl or C -C alkyl substituted by one or more halogen atoms; R represents a group R (X) &mdash;(ALK)&mdash; wherein R represents hydrogen, a C -C alkyl, C -C alkenyl, C -C alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C -C )alkyl, (C -C )alkoyy, hydroxy, mercapto, (C -C )alkylthio, amino, halo, trifluoromethyl, cyano, nitro, &mdash;COOH, &mdash;CONH , &mdash;COOR , &mdash;NHCOR , &mdash;CONHR , &mdash;NHR , &mdash;NR R , or &mdash;CONR R wherein R and R are independently a (C -C )alkyl group, and ALK represents a straight or branched divalent C -C alkylene, C -C alkenylene, or C -C alkynylene radical, which may be interrupted by one or more non-adjacent &mdash;NH&mdash;, &mdash;O&mdash; or &mdash;S&mdash; linkages, X represents &mdash;NH&mdash;, &mdash;O&mdash; or &mdash;S&mdash;, and n is 0 or 1, R represents hydrogen or C -C alkyl, R represents the characterising group or a natural or non-natural &agr; amino acid in which any functional groups may be protected; and R represents an ester or thioester group.

N-formyl hydroxylamine derivatives as antibacterial agents

Compounds of formula (I) are antibacterials wherein: R represents hydrogen, or C -C alkyl or C -C alkyl substituted by one or more halogen atoms; R represents a group R &mdash;(X) &mdash;(ALK) &mdash; wherein R represents hydrogen, or a C -C alkyl, C -C alkenyl, C -C alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C -C )alkyl, (C -C )alkoxy, hydroxy, mercapto, (C -C )alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, &mdash;COOH, &mdash;CONH , &mdash;COOR , &mdash;NHCOR , &mdash;CONHR , &mdash;NHR , &mdash;NR R , or &mdash;CONR R wherein R and R are independently a (C -C )alkyl group, and ALK represents a straight or branched divalent C -C alkylene, C -C alkenylene, or C -C alkynylene radical, and may be interrupted by one or more non-adjacent &mdash;NH&mdash;, &mdash;O&mdash; or &mdash;S&mdash; linkages, X represents &mdash;NH&mdash;, &mdash;O&mdash; or &mdash;S&mdash;, and m and n are independently 0 or 1; and A represents a group as defined in the specification.

Stem cell inhibiting proteins

This invention relates to mutants of human RANTES (hRANTES) which, relative to the wild-type molecule, have a reduced tendency to aggregate into large multimeric complexes at physiological ionic strength and pH, and are less pro-inflammatory.

Disaggregated mutant human RANTES

Release and mobilization of haematopoietic cells

Proteinaceous molecules with stem cell inhibition activity are analogues of LD78 or MIP-1.alpha. which have mutations to prevent or reduce multimer formation beyond certain stages (for example a dodecamer). Aggregate formation is therefore inhibited, and the resulting low molecular weight monomers (or oligomers) have improved solution properties leading to enhanced productivity and greater therapeutic utility as stem cell protective agents, which are useful in tumour therapy.

Growing community of inventors

Oxford, United Kingdom

Michael George Hunter